Pricing Log in Create free account
Saturday 7 November 2026 Export SLN’s income statement to Excel — free account

Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024.

Revenue
+197.2%
EPS
+54.4%
Free cash flow
+107.0%

Quarter to June 2026, against a year earlier

19.73 0.01 +0.05%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−38.7×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 1,230.00
Revenue ttm 0.84
Net income ttm (59.95)
Free cash flow ttm (42.26)
Net debt Q (72.05)
Valuation
P/E 0.00
Forward P/E (38.70) (negative: loss-making)
Price / sales 1,110.83 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 24.23 (above 6: high)
Financial health
Current ratio Q 7.42 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (2.68)
Growth
Revenue growth Q +197.18% (above 0%: growing)
Operating income growth Q +42.14% (above 0%: growing)
EPS, this year +42.06% (at or above 15%: strong)
EPS, next year A −51.08% (below 0%: weak)
Revenue, next year A −21.57% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −1.68% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1,025×, against a ten-year median of 14.0×; over the ten years it ranged from −0.1× in 2025 to 1,026× in 2026.
P/S against its own 10 years 99.48%
10-year low 10-year high
P/B against its own 10 years 72.54%
10-year low 10-year high
EV/Sales against its own 10 years 99.48%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 69 147 85 72
Receivables 23 25 22 9
Inventory — — — —
Other 12 15 12 13
103 187 119 94
2023 2024 2025 Q'26
Payables 16 16 13 13
ST’ Debt — — — —
Other 7 0 0 —
22 17 14 13

Compound Annual Growth %

10y 5y 3y
Sales — (39.74%) (70.44%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 39.89% 31.66%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.32 Actual −0.26

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.40 −0.45 Miss by 0.05
Q4 FY25 −0.32 −0.25 Beat by 0.07
Q1 FY26 −0.33 −0.32 Beat by 0.01
Q2 FY26 −0.32 −0.26 Beat by 0.06
Q3 FY26 −0.26 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.32) (0.26) — — —
’25 (0.60) (0.57) (0.45) (0.25) (1.89)
’24 (0.05) (0.42) (0.75) 0.27 (0.99)
’23 (0.35) (0.36) (0.28) (0.47) (1.46)
’22 (0.35) (0.50) (0.25) (0.46) (1.56)
’21 — (0.32) (0.46) (0.30) (1.83)
’20 — (0.17) — (0.36) (1.53)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 — — — —
’25 0 0 0 0 1
’24 16 1 1 25 43
’23 14 11 4 3 32
’22 8 5 4 5 22
’21 — 11 4 12 17
’20 — 2 — 8 7
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 2 — — —
’25 (12) (22) (11) (17) (62)
’24 (9) (5) (26) (27) (68)
’23 (9) (19) (6) (15) (49)
’22 (19) (9) (9) (18) (56)
’21 — 19 (8) (14) 9
’20 — 1 — (14) (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 2 — — —
’25 (12) (22) (11) (17) (62)
’24 (9) (5) (26) (28) (68)
’23 (9) (45) (7) (15) (50)
’22 (19) (9) (9) (19) (57)
’21 — 19 (8) (14) 8
’20 — 1 — (14) (14)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 0 — 0 7 17 22 32 43 1 1 (5.7%) 0 1 0 (25.5%)
Gross margin, % 59.74 (2,606.80) 0.00 0.00 31.34 39.94 37.83 59.34 72.70 61.54 79.50 +1.8 pt
EBT (13) (7) (35) (38) (46) (63) (59) (53) (44) (89) (60) +24.0%
EBT margin, % (1,345.71) (23,599.51) 0.00 (9,372.37) (657.81) (369.36) (270.66) (168.35) (102.79) (15,849.91) 0.00 (14,504.2) pt
Net income (10) 0 (31) 0 (46) (63) (59) (54) (45) (89) (60) +26.9%
Per share, $
Per share, $ Revenue 0.04 0.00 0.00 0.02 0.26 0.58 0.67 0.85 0.94 0.01 0.00 (12.7%)
Earnings (0.44) (0.10) (1.35) (1.32) (1.53) (1.83) (1.56) (1.46) (0.99) (1.89) (1.28) +17.6%
Cash flow (0.52) (0.59) (1.22) 0.11 (0.51) 0.32 (1.75) (1.33) (1.46) (1.32) (0.89) +11.0%
Capex 0.00 0.00 0.00 0.00 (0.02) (0.06) (0.02) 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.52) (0.59) (1.22) 0.11 (0.53) 0.25 (1.76) (1.33) (1.47) (1.32) (0.89) +11.0%
Book value 2.82 3.39 2.44 1.46 0.43 0.40 0.85 0.59 2.90 1.32 0.81 (8.1%)
Shares, m 24 28 23 25 27 30 32 37 46 47 47 +8.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 — 0.00 0.00 20.33 21.85 21.74 7.36 513.72 1,110.83 65.0
P/B 12.43 12.43 — 12.43 52.52 45.82 17.32 31.29 2.37 4.61 24.23 21.2
EV/Sales 0.00 0.00 — 0.00 0.00 16.50 17.78 19.57 3.95 361.63 1,025.03 46.6
EV/FCF (291.34) (291.34) — (291.34) (108.15) (36.56) (6.83) (12.51) (2.52) (3.24) (20.32) (116.0)
Cash, $m
Cash, $m Operating cash flow (12) (17) (29) 3 (14) 9 (56) (49) (68) (62) (42) +19.8%
Capex (1) 0 0 0 (1) (2) (1) 0 0 0 0 (24.2%)
Free cash flow (12) (17) (29) 3 (14) 8 (57) (50) (68) (62) (42) +19.8%
Balance, $m
Balance, $m Working capital 50 78 42 48 65 98 92 81 171 105 82 +8.6%
Net debt (48) (79) (43) (58) (50) (101) (88) (69) (147) (85) (72) +6.5%
Shareholders’ equity 67 96 57 36 12 12 27 22 134 62 38 (0.8%)
Returns, %
Returns, % ROA (14.55) (8.18) (47.55) (103.54) (48.07) (44.66) (37.76) (42.97) (28.13) (53.05) (44.14) (38.5) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (15.14) (3.46) (41.16) (70.17) (173.84) (464.06) (256.66) (220.02) (58.08) (90.27) (90.41) (75.1) pt
People
People Employees — — — 58 74 105 122 109 116 88 — +7.2%
Revenue/emp, $m 0.00 0.00 — 0.01 0.10 0.16 0.18 0.29 0.37 0.01 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Silence Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GHRS GH Research PLC $1.3B — (loss-making) — — n/m −66.62% (below 0%: shrinking) 0.00% 0.00% Compare
URGN Urogen Pharma $1.3B — (loss-making) — (loss-making) +223.85% (above 0%: growing) n/m +63.95% (above 0%: growing) 91.57% 9.36% Compare
OMER Omeros Corporation $1.2B 9.8× 2.1× +35.46% (above 0%: growing) n/m +118.70% (above 0%: growing) 97.20% 0.26% Compare
SLN Silence Therapeutics PLC Sponsored ADR $1.2B — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00%
DRTS Alpha Tau Medical Ltd. $1.2B — (loss-making) — — n/m −30.42% (below 0%: shrinking) 0.00% 0.00% Compare
LBRX LB Pharmaceuticals Inc $1.2B — (loss-making) — — n/m −579.03% (below 0%: shrinking) — 0.00% Compare
NKTR Nektar Therapeutics $1.2B — (loss-making) — (loss-making) −9.34% (below 0%: shrinking) n/m −65.73% (below 0%: shrinking) 100.00% (417.94%) Compare
MNKD MannKind Corporation $1.2B — (loss-making) — (loss-making) +24.04% (above 0%: growing) n/m −267.69% (below 0%: shrinking) 0.00% (2.14%) Compare
AVLN Avalyn Pharma Inc. $1.2B — (loss-making) — — n/m — — 0.00% Compare
Median of peers $1.2B — — +29.75% — −65.73% 45.79% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together 3.00%
Richard Griffiths 24.40%
Robert Keith 8.70%
TCG Crossover Fund I, L.P. 6.40%
Invus Public Equities Advisors, LLC 6.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Silence Therapeutics PLC Sponsored ADR (SLN) Latest News

20 Oct

Impact 3 · · Zacks

19 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Insider Monkey
Impact 4 · · Proactive Investors
Impact 4 · · Investing.com
Impact 4 · · Business Wire

14 Oct

Impact 4 · · Zacks

13 Oct

Impact 3 · · Zacks

14 Aug

Impact 3 ·

11 Aug

Impact 4 ·
Impact 4 · · MarketBeat
Impact 3 ·

10 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·

9 Aug

Impact 3 ·

30 Jun

Impact 3 ·

25 Jun

Impact 4 · · Zacks

17 Jun

Impact 3 ·

11 Jun

Impact 4 ·

16 Apr

Impact 4 · · Zacks

5 Mar

Impact 4 · · Business Wire
Impact 3 · · Zacks

12 Jan

Impact 3 · · MT Newswires

21 Dec

Impact 4 · · Simply Wall St.

15 Dec

Impact 4 ·

30 Nov

Impact 3 ·

9 Nov

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.

6 Nov

Impact 4 · · Business WireMT NewswiresGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com

23 Oct

Impact 4 · · Business Wire
stockrow.com/SLN · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com